{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:56:38Z","timestamp":1767135398237,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd013382","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000}}],"reference-count":140,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013382.pub2","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T06:48:11Z","timestamp":1688712491000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status"],"prefix":"10.1002","volume":"2023","author":[{"given":"Rolof GP","family":"Gijtenbeek","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Medical Center Leeuwarden; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Medical Center Leeuwarden; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben JW","family":"Venmans","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Medical Center Leeuwarden; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke HM","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Medical Center Leeuwarden; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke","family":"Ten Brinke","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Medical Center Leeuwarden; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthonie J","family":"Van der Wekken","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; University of Groningen, University Medical Center Groningen; Groningen Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter H","family":"van Geffen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Medical Center Leeuwarden; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/bjc.2012.284","article-title":"Vinorelbine and gemcitabine versus vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group","volume":"107","author":"Gr\u00f8nberg","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/JTO.0b013e318031cd62","article-title":"Single-agent pemetrexed or sequential pemetrexed\/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial","volume":"2","author":"Gridelli","year":"2007","journal-title":"Journal of Thoracic Oncology"},{"issue":"19","key":"10.1002\/14651858.CD013382.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","article-title":"Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer","volume":"27","author":"Gr\u00f8nberg","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013382.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/cncr.23019","article-title":"Weekly docetaxel versus docetaxel\/gemcitabine in the treatment of elderly or poor performance status patients with advanced non-small cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network","volume":"110","author":"Hainsworth","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cllc.2011.03.015","article-title":"Docetaxel versus vinorelbine in elderly patients with advanced non-small-cell lung cancer: a Hellenic Oncology Research Group randomized phase III study","volume":"12","author":"Karampeazis","year":"2011","journal-title":"Clinical Lung Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1556-0864(15)30041-1","article-title":"Gemcitabine versus gemcitabine\u2013carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group","volume":"2","author":"Kosmidis","year":"2007","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0007|cit7","first-page":"175","article-title":"Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2","volume":"32","author":"Kosmidis","year":"2012","journal-title":"Anticancer Research"},{"issue":"4","key":"10.1002\/14651858.CD013382.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1200\/JCO.2005.04.9452","article-title":"Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599","volume":"25","author":"Langer","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013382.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1634\/theoncologist.6-suppl_1-8","article-title":"Long term analysis of survival in the European randomized trial comparing vinorelbine\/cisplatin to vindesine\/cisplatin and vinorelbine alone in advanced non-small cell lung cancer","volume":"6","author":"Le Chevalier","year":"2001","journal-title":"Oncologist"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD013382.pub2-BIB0011|cit11","first-page":"S808","article-title":"IPSOS: results from a phase III study of first-line (1L) atezolizumab (atezo) versus single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen","volume":"33","author":"Lee","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0012|cit12","unstructured":"A study of atezolizumab compared with chemotherapy in treatment na\u00efve participants with locally advanced or recurrent or metastatic non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy clinicaltrials.gov\/show\/nct03191786 1 9"},{"issue":"16 suppl","key":"10.1002\/14651858.CD013382.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"9011","DOI":"10.1200\/JCO.2022.40.16_suppl.9011","article-title":"Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (\u2265 70 years) patients with advanced non-small cell lung cancer (Energy-GFPC 06-2015 study)","volume":"40","author":"Lena","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lungcan.2013.04.008","article-title":"Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study","volume":"81","author":"Morabito","year":"2013","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jgo.2015.02.002","article-title":"Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)","volume":"6","author":"Des Guetz","year":"2015","journal-title":"Journal of Geriatric Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.lungcan.2010.03.003","article-title":"Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)","volume":"70","author":"Mor\u00e8re","year":"2010","journal-title":"Lung Cancer"},{"issue":"9796","key":"10.1002\/14651858.CD013382.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","article-title":"Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial","volume":"378","author":"Quoix","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1200\/JCO.2009.21.9766","article-title":"Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer","volume":"27","author":"Reynolds","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/COC.0b013e318201a0f3","article-title":"Randomized phase II study of carboplatin-paclitaxel or gemcitabine- vinorelbine in patients with advanced non small cell lung cancer and a performance status of 2: West Japan thoracic oncology Group 0004","volume":"35","author":"Saito","year":"2012","journal-title":"American Journal of Clinical Oncology: Cancer Clinical Trials"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/LCTT.S142972","article-title":"65plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed\/ carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"8","author":"Schuette","year":"2017","journal-title":"Lung Cancer: Targets and Therapy"},{"issue":"9","key":"10.1002\/14651858.CD013382.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/cncr.30986","article-title":"Randomized phase 2 trial of pemetrexed, pemetrexed\/bevacizumab, and pemetrexed\/carboplatin\/bevacizumab in patients with stage IIIB\/IV non small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2","volume":"124","author":"Spigel","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013382.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1002\/1097-0142(20011115)92:10","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase III trial in patients with metastatic non small cell lung carcinoma","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013382.pub2-BIB0025|cit25","first-page":"389","article-title":"An open-label randomized controlled trial comparing the efficacy and safety of pemetrexed-carboplatin versus (weekly) paclitaxel-carboplatin as first-line chemotherapy in advanced non-squamous non-small cell lung cancer","volume":"99","author":"Yadav","year":"2021","journal-title":"Oncology (Switzerland)"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.2012.48.1911","article-title":"Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non\u2013small-cell lung cancer and Eastern Cooperative Oncology Group Performance Status of 2","volume":"31","author":"Zukin","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"Issue 1-2","key":"10.1002\/14651858.CD013382.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21608\/resoncol.2014.885","article-title":"Gemcitabine-docetaxel versus gemcitabine-cisplatin as first-line therapy in patients with advanced non-small cell lung cancer","volume":"10","author":"Al-Gizawy","year":"2014","journal-title":"Research in Oncology"},{"issue":"1 suppl 2","key":"10.1002\/14651858.CD013382.pub2-BIB0028|cit28","first-page":"21","article-title":"Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group","volume":"XII","author":"Anderson","year":"1985","journal-title":"Seminars in Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013382.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1054\/bjoc.2000.1307","article-title":"Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer \u2013 a randomized trial with quality of life as the primary outcome","volume":"83","author":"Anderson","year":"2000","journal-title":"British Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD013382.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S1961","DOI":"10.1016\/j.jtho.2017.09.831","article-title":"Randomized phase 2 study comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in treatment-na\u00efve advanced non-Sq NSCLC (CLEAR study)","volume":"12","author":"Atagi","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.lungcan.2006.05.003","article-title":"Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial","volume":"53","author":"Belani","year":"2006","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1002\/14651858.CD013382.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/jnci\/85.10.794","article-title":"Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer","volume":"85","author":"Cartei","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Cellerino R Tummarello D Guidi F Isidori P Raspugli M Biscottini B A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer Journal of Clinical Oncology 1991 9 1453 61","DOI":"10.1200\/JCO.1991.9.8.1453"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.bjc.6602011","article-title":"Gemcitabine with either paclitaxel or vinorelbine versus paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients","volume":"91","author":"Comella","year":"2004","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF02940294","article-title":"A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group","volume":"26","author":"Crino","year":"1990","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013382.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"s125","DOI":"10.1016\/0169-5002(95)00428-4","article-title":"Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research","volume":"12","author":"Crino","year":"1995","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1200\/JCO.1999.17.10.3188","article-title":"Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life","volume":"17","author":"Cullen","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cncr.11535","article-title":"Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non small cell lung carcinoma","volume":"98","author":"Danson","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013382.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cncr.29132","article-title":"Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced\/metastatic non-small cell lung cancer","volume":"121","author":"Doebele","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jnci\/91.1.66","article-title":"Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer","volume":"91","author":"The Elderly Lung Cancer Vinorelbine Italian Study Group","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10637-005-2478-z","article-title":"Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study","volume":"24","author":"Esteban","year":"2006","journal-title":"Investigational New Drugs"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejca.2017.05.037","article-title":"Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial","volume":"83","author":"Ferry","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"16","key":"10.1002\/14651858.CD013382.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group","volume":"21","author":"Fossella","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Ganz PA Figlin RA Haskell CM Soto NL Siau J Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989 63 1271 8","DOI":"10.1002\/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-5002(02)00076-4","article-title":"Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study","volume":"37","author":"Gebbia","year":"2002","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-5002(02)00444-0","article-title":"Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale","volume":"39","author":"Gebbia","year":"2003","journal-title":"Lung Cancer"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013382.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-5002(01)00417-2","article-title":"Comparison of docetaxel\/cisplatin to docetaxel\/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial","volume":"34","author":"Georgoulias","year":"2001","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013382.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1200\/JCO.1998.16.6.2133","article-title":"Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer","volume":"16","author":"Giaccone","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013382.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3816\/CLC.2007.n.032","article-title":"Paclitaxel\/carboplatin\/gemcitabine versus gemcitabine\/vinorelbine in advanced non-small-cell lung cancer: a phase II\/III study of the Minnie Pearl cancer Research Network","volume":"8","author":"Greco","year":"2007","journal-title":"Clinical Lung Cancer"},{"issue":"8","key":"10.1002\/14651858.CD013382.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/oxfordjournals.annonc.a010761","article-title":"Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: a phase III multicentre randomised trial","volume":"7","author":"Gridelli","year":"1996","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"16","key":"10.1002\/14651858.CD013382.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2003.06.099","article-title":"Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Gridelli","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0169-5002(01)00493-7","article-title":"Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial","volume":"37","author":"Grigorescu","year":"2002","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.bjc.6603869","article-title":"Vinorelbine\/carboplatin vs gemcitabine\/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity","volume":"97","author":"Helbekkmo","year":"2007","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD013382.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0959-8049(97)10122-8","article-title":"Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial","volume":"34","author":"Helsing","year":"1998","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.lungcan.2010.05.007","article-title":"Randomized phase II study of gemcitabine and carboplatin +\/- sequential docetaxel in non-small cell lung cancer","volume":"71","author":"Hillerdal","year":"2011","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00280-017-3289-6","article-title":"Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer","volume":"79","author":"Jang","year":"2017","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-5002(01)00239-2","article-title":"Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study","volume":"34","author":"Jeli\u0107","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/1097-0142(19910515)67:10<2443::AID-CNCR2820671008>3.0.CO;2-K","article-title":"Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer","volume":"67","author":"Kaasa","year":"1991","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jgo.2016.05.002","article-title":"Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study","volume":"8","author":"Karampeazis","year":"2017","journal-title":"Journal of Geriatric Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.annonc.a058769","article-title":"A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer: a study of the hellenic co-operative oncology group for lung cancer trials","volume":"5","author":"Kosmidis","year":"1994","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013382.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/annonc\/mdv050.29","article-title":"A prospective randomized phase III study of palliative chemotherapy versus best supportive care in elderly patients with advanced non-small cell lung cancer: survival analysis and ECOG performance status regression analysis","volume":"26","author":"Kumar","year":"2015","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/JTO.0b013e318031d06f","article-title":"A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and\/or are elderly","volume":"2","author":"Leong","year":"2007","journal-title":"Journal of Thoracic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013382.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1023\/A:1008207731111","article-title":"Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer","volume":"8","author":"Manegold","year":"1997","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1440-1843.1996.tb00010.x","article-title":"A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer","volume":"1","author":"Masutani","year":"1996","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0066|cit66","unstructured":"Paclitaxel and carboplatin chemotherapy compared with standard chemotherapy in treating patients with stage III or stage IV non-small cell lung cancer that cannot be removed during surgery clinicaltrials.gov\/show\/nct00004887"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0067|cit67","unstructured":"Pemetrexed with or without carboplatin for elderly non-squamous non-small cell lung cancer clinicaltrials.gov\/show\/nct01593293"},{"issue":"4","key":"10.1002\/14651858.CD013382.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2005.03.2722","article-title":"Adding gemcitabine to paclitaxel\/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study","volume":"24","author":"Paccagnella","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdf128","article-title":"Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study","volume":"13","author":"Perol","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0070|cit70","first-page":"341","article-title":"Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study","volume":"78","author":"Quoix","year":"1991","journal-title":"Bulletin du Cancer"},{"issue":"13","key":"10.1002\/14651858.CD013382.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/jnci\/92.13.1074","article-title":"Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer","volume":"92","author":"Ranson","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD013382.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.1988.6.4.633","article-title":"Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer \u2013 report of a Canadian multicenter randomized trial","volume":"6","author":"Rapp","year":"1988","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013382.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/JTO.0b013e318226b5fa","article-title":"A randomized phase 3 trial comparing pemetrexed\/carboplatin and docetaxel\/carboplatin as first-line treatment for advanced, non squamous non-small cell lung cancer","volume":"6","author":"Rodrigues-Pereira","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00000421-198706000-00017","article-title":"A randomized study comparing platinum, doxorubicin, and VP-16 with platinum, 4\u2032-epidoxorubicin, and VP-16 in patients with non-small-cell lung cancer","volume":"10","author":"Rosell","year":"1987","journal-title":"American Journal of Clinical Oncology: Cancer Clinical Trials"},{"issue":"10","key":"10.1002\/14651858.CD013382.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdf332","article-title":"Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial","volume":"13","author":"Rosell","year":"2002","journal-title":"Annals of Oncology"},{"issue":"66","key":"10.1002\/14651858.CD013382.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/1097-0142(19900701)66:1<130::AID-CNCR2820660123>3.0.CO;2-P","article-title":"Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP Trial. Italian Lung Cancer Task Force","volume":"1","author":"Rosso","year":"1990","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0169-5002(00)00094-5","article-title":"A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)","volume":"27","author":"Roszkowski","year":"2000","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.1985.3.1.72","article-title":"Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V \u2013 a randomized comparison of four cisplatin-containing regimens","volume":"3","author":"Ruckdeschel","year":"1985","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.1986.4.1.14","article-title":"A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer","volume":"4","author":"Ruckdeschel","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013382.pub2-BIB0080|cit80","first-page":"945","article-title":"Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer","volume":"69","author":"Shinkai","year":"1985","journal-title":"Cancer Treatment Reports"},{"issue":"Suppl 56","key":"10.1002\/14651858.CD013382.pub2-BIB0081|cit81","first-page":"P4617","article-title":"Triplet chemotherapy (paclitaxel\/gemcitabine\/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine\/cisplatin): a randomized phase III trial in 443 NSCLC patients","volume":"40","author":"Sorensen","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD013382.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/thx.2003.020164","article-title":"Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life","volume":"59","author":"Spiro","year":"2004","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD013382.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/annonc\/mdh260","article-title":"Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial","volume":"15","author":"Stathopoulos","year":"2004","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0169-5002(99)00067-7","article-title":"Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer","volume":"26","author":"ten Bokkel Huinink","year":"1999","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-5002(99)00017-3","article-title":"Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy","volume":"24","author":"Thongprasert","year":"1999","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00000421-198810000-00012","article-title":"Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide","volume":"11","author":"Veronesi","year":"1988","journal-title":"American Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013382.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/sj.bjc.6601283","article-title":"First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial","volume":"89","author":"Wachters","year":"2003","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013382.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/bjc.1990.135","article-title":"A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer","volume":"61","author":"Woods","year":"1990","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0089|cit89","unstructured":"Effect of pembrolizumab with or without carboplatin and paclitaxel on immune response in patients with recurrent or stage IIIB-IV non-small cell lung cancer clinicaltrials.gov\/show\/nct02581943"},{"issue":"17","key":"10.1002\/14651858.CD013382.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.critrevonc.2015.03.010","article-title":"What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis","volume":"95","author":"Bronte","year":"2015","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"7","key":"10.1002\/14651858.CD013382.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/0959-8049(95)00664-8","article-title":"Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution","volume":"32A","author":"Buccheri","year":"1996","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/apm.2016.03.02","article-title":"Inter-rater reliability in performance status assessment among health care professionals: a systematic review","volume":"5","author":"Chow","year":"2016","journal-title":"Annals of Palliative Medicine"},{"issue":"13","key":"10.1002\/14651858.CD013382.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2005.03.045","article-title":"Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature","volume":"23","author":"D'Addario","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2017.04.005","article-title":"Trends in treatment and relative survival among non-small cell lung cancer patients in the Netherlands (1990-2014): disparities between younger and older patients","volume":"108","author":"Driessen","year":"2017","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.1986.4.5.702","article-title":"Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study","volume":"4","author":"Finkelstein","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1183\/13993003.01695-2015","article-title":"Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy","volume":"48","author":"Fiteni","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD013382.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"E647","DOI":"10.1016\/j.cllc.2020.05.019","article-title":"Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer","volume":"21","author":"Gijtenbeek","year":"2020","journal-title":"Clinical Lung Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013382.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"00239","DOI":"10.1183\/23120541.00239-2022","article-title":"Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated non small cell lung cancer","volume":"8","author":"Gijtenbeek","year":"2022","journal-title":"ERJ Open Research"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"100592","DOI":"10.1016\/j.lanepe.2023.100592","article-title":"Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in the Netherlands: a retrospective, nationwide registry study","volume":"27","author":"Gijtenbeek","year":"2023","journal-title":"Lancet Regional Health \u2013 Europe"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0104|cit104","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2022"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.esmoop.2021.100355","article-title":"First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an international expert panel meeting by the Italian Association of Thoracic Oncology","volume":"7","author":"Gridelli","year":"2022","journal-title":"ESMO Open"},{"issue":"21","key":"10.1002\/14651858.CD013382.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"04785","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"S0923-7534(22)","author":"Hendriks","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0108|cit108","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD013382.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013382.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013382.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jtho.2017.02.012","article-title":"Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401)","volume":"12","author":"Iwama","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1016\/j.cllc.2018.05.014","article-title":"Clinical characteristics and prognosis of patients with advanced non small-cell lung cancer who are ineligible for clinical trials","volume":"19","author":"Kawachi","year":"2018","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/j.cllc.2018.05.005","article-title":"A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: study protocol","volume":"19","author":"Kogure","year":"2018","journal-title":"Clinical Lung Cancer"},{"issue":"22","key":"10.1002\/14651858.CD013382.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.06.1044","article-title":"Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904)","volume":"24","author":"Kudoh","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial Including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013382.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0022681","article-title":"Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"6","author":"Lima","year":"2011","journal-title":"PLOS One"},{"issue":"9","key":"10.1002\/14651858.CD013382.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0120|cit120","unstructured":"National Institute for Health and Care Excellence Lung cancer: diagnosis and management; guideline 122 www.nice.org.uk\/guidance\/ng122\/"},{"issue":"April","key":"10.1002\/14651858.CD013382.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.lungcan.2021.04.001","article-title":"Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy","volume":"155","author":"Noordhof","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"1995","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002139","article-title":"Chemotherapy for non-small cell lung cancer","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007309.pub2","article-title":"Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"28","key":"10.1002\/14651858.CD013382.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.22.00825","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline","volume":"40","author":"Owen","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD013382.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2013 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study","volume":"13","author":"Reck","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0129|cit129","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"issue":"10","key":"10.1002\/14651858.CD013382.pub2-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010463.pub2","article-title":"Chemotherapy for advanced non-small cell lung cancer in the elderly population","author":"Santos","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"21","key":"10.1002\/14651858.CD013382.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013382.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013382.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1183\/09031936.00034507","article-title":"Chemotherapy improves low performance status lung cancer patients","volume":"30","author":"Sculier","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD013382.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JTO.0b013e31816de2b8","article-title":"The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition","volume":"3","author":"Sculier","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013382.pub2-BIB0136|cit136","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009256.pub3","article-title":"Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer","author":"Vasconcellos","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013382.pub2-BIB0138|cit138","unstructured":"World Health Organization WHO Handbook for Reporting Results of Cancer Treatment WHO Offset Publication 1979 48 4"},{"issue":"1","key":"10.1002\/14651858.CD013382.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/ijo.2015.3219","article-title":"Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (review)","volume":"48","author":"Zinner","year":"2016","journal-title":"International Journal of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013382.pub2-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013382","article-title":"Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status","author":"Gijtenbeek","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T22:46:02Z","timestamp":1718750762000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013382.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":140,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013382.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}